Tomas Pascual
Overview
Explore the profile of Tomas Pascual including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
1631
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Papakonstantinou A, Villacampa G, Navarro V, Oliveira M, Valachis A, Pascual T, et al.
EClinicalMedicine
. 2025 Mar;
81:103116.
PMID: 40034565
Background: Multiple trials have evaluated escalation strategies of endocrine therapy for early breast cancer, including ovarian function suppression (OFS) and aromatase inhibitors (AI) in premenopausal patients and extended endocrine therapy....
2.
Vidal M, Falato C, Pascual T, Sanchez-Bayona R, Munoz-Mateu M, Cebrecos I, et al.
Clin Cancer Res
. 2025 Jan;
PMID: 39820652
Introduction: Elacestrant has shown significantly prolonged progression-free survival compared to standard-of-care endocrine therapy in estrogen receptor-positive (ER-positive), HER2-negative metastatic breast cancer (BC), while potential benefit in early-stage disease requires further...
3.
Tolosa P, Pascual T, Martinez-Saez O, Hernando C, Servitja S, Fernandez Abad M, et al.
Eur J Cancer
. 2025 Jan;
217:115219.
PMID: 39779447
Introduction: The prognostic value of PAM50 intrinsic subtypes (IS), cell cycle, and immune-related gene expression in HR+ /HER2- advanced breast cancer (BC) treated with CDK4/6 inhibitors (CDK4/6i) and endocrine therapy...
4.
Schettini F, Nucera S, Pascual T, Martinez-Saez O, Sanchez-Bayona R, Conte B, et al.
Cancer Treat Rev
. 2024 Dec;
132:102865.
PMID: 39709655
Introduction: Antibody-drug conjugates (ADCs) trastuzumab-deruxtecan (T-DXd) and sacituzumab-govitecan (SG) provided significant progression-free survival (PFS) and overall survival (OS) improvements over chemotherapy (CT) in pretreated hormone receptor-positive (HR+) and triple-negative (TN)/HER2-low...
5.
Fernandez-Martinez A, Fernandez-Martinez A, Tanioka M, Tanioka M, Ahn S, Ahn S, et al.
Ann Oncol
. 2024 Dec;
PMID: 39706338
Background: In human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (EBC), we investigated tumor and immune changes during neoadjuvant treatment and their impact on residual disease (RD) biology...
6.
Pernas S, Sanfeliu E, Villacampa G, Salvador J, Perello A, Gonzalez X, et al.
NPJ Breast Cancer
. 2024 Nov;
10(1):101.
PMID: 39592624
With the incorporation of cyclin-dependent kinase inhibitors in early breast cancer (BC), a better identification of biomarkers is needed. The PROMETEO II trial aimed to evaluate the antitumor activity of...
7.
Villacampa G, Cresta Morgado P, Carita L, Navarro V, Pascual T, Dienstmann R
Cancer Treat Rev
. 2024 Oct;
131:102847.
PMID: 39454548
Background: Combining antibody-drug conjugate (ADCs) with immune checkpoint inhibitors (ICIs) is emerging as a promising treatment option to increase efficacy outcomes. However, concerns arise regarding the safety of these combinations,...
8.
Waks A, Martinez-Saez O, Tarantino P, Braso-Maristany F, Pascual T, Cortes J, et al.
Nat Rev Clin Oncol
. 2024 Sep;
21(11):818-832.
PMID: 39271787
HER2-targeted therapies for patients with HER2 breast cancer are rapidly evolving, offering a range of more complex and personalized treatment options. Currently, an array of anti-HER2 monoclonal antibodies, tyrosine kinase...
9.
Villacampa G, Navarro V, Matikas A, Ribeiro J, Schettini F, Tolosa P, et al.
JAMA Oncol
. 2024 Aug;
10(10):1331-1341.
PMID: 39207778
Importance: Recent studies have investigated the combination of immune checkpoint inhibitors (ICIs) with (neo)adjuvant chemotherapy in early-stage breast cancer. However, there is an ongoing debate about the optimal approach for...
10.
Lorman-Carbo N, Martinez-Saez O, Fernandez-Martinez A, Galvan P, Chic N, Garcia-Fructuoso I, et al.
Sci Rep
. 2024 Jul;
14(1):16030.
PMID: 38992220
This study examines the biological effects of palbociclib and ribociclib in hormone receptor-positive breast cancer, pivotal to the HARMONIA prospective phase III clinical trial. We explore the downstream impacts of...